ControlVit mobile app sustains patient empowerment in chronic heart failure after 6-month discontinuation.
Background
Chronic heart failure (HF) is a debilitating condition characterized by progressive cardiac dysfunction, leading to frequent hospitalizations and reduced quality of life. Standard care often involves complex medication regimens and lifestyle modifications, which can be challenging for patients to adhere to. Patient empowerment, fostering self-management and active participation in care, is crucial for improving long-term outcomes and reducing the burden of disease. Digital health interventions, such as mobile applications, offer a promising avenue to enhance patient engagement and support self-care, potentially bridging gaps in traditional care models for HF management.
Study Design
This open-label, randomized controlled trial enrolled 140 patients with chronic heart failure (mean age 67 y, 28.6% women). Participants were randomized to either standard HF management plus the ControlVit mobile application for 6 months or standard care alone. After the initial 6-month intervention period, app use was discontinued for all participants, who were then followed for an additional 6 months. The primary endpoint was a composite of death or HF-related hospital readmission at 12 months. Secondary outcomes included changes in body weight, natriuretic peptide levels, NYHA functional class, and patient empowerment, assessed using the Empowerment Evaluation Scale (EES).
Results
At 12 months, the primary composite outcome of death or HF-related hospital readmission showed no significant difference between groups. 8 patients (11.4%) in the intervention group experienced the primary outcome compared to 3 patients (4.3%) in the control group (relative risk: 2.62; 95% CI: 0.73-9.52; P=.122). > Empowerment levels were significantly higher among ControlVit app users compared with controls, even 6 months after app discontinuation (EES score: 4.68 ± 0.36 vs. 4.40 ± 1.91; P=.012). This suggests a lasting behavioral impact beyond active app use. Additionally, the use of SGLT2 inhibitors and ARNi medications increased significantly in both groups during the 12-month follow-up (ControlVit: from 60% to 85%, P<.001; Control: from 51.4% to 75%, P<.001), indicating a general trend in medication optimization within the study population, independent of the app. No specific data on body weight, natriuretic peptide levels, or NYHA functional class changes were reported in the abstract.
Why It Matters
This study highlights that while a telemonitoring app like ControlVit may not directly reduce hard clinical endpoints like mortality or readmissions in chronic heart failure patients after discontinuation, it can foster sustained patient empowerment. This suggests that digital health tools can instill lasting self-management behaviors and improve patient confidence, even after the active intervention period ends. For individuals managing complex conditions like HF, enhanced empowerment can lead to better adherence to treatment plans and improved quality of life, which are critical, often overlooked, aspects of care. Clinically, this implies that integrating short-term digital interventions could provide long-term behavioral benefits, potentially complementing traditional care without requiring indefinite app use. Further research could explore how this empowerment translates into other patient-reported outcomes or indirect clinical benefits.